Advertisement

Enhancing the Value of PCSK9 Monoclonal Antibodies by Identifying Patients Most Likely to Benefit

Last Updated: Thursday, 16-May-2019 19:15:00 EDT

Enhancing the Value of PCSK9 Monoclonal Antibodies by Identifying Patients Most Likely to Benefit

A Scientific Statement from the National Lipid Association

Jennifer G Robinson, MD, MPH, Manju Bengularu Jayanna, MBBS, Alan S. Brown, MD, FNLA, Karen Aspry, MD, MS, FNLA, Carl Orringer, MD, FNLA, Edward A. Gill, MD, FNLA, Anne Goldberg, MD, FNLA, Laney K. Jones PharmD, MPH, Kevin Maki, PhD, Dave L. Dixon, PharmD, Joseph Saseen PharmD, FNLA, Daniel Soffer, MD, FNLA, FACP

Highlights: 

  • Initial pricing limited uptake of highly effective proprotein convertase subtilisin/kexin type 9 monoclonal antibodies.

  • Recent price reductions call for new guidance in this National Lipid Association statement.

  • Value assessment may improve access to proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for appropriate patient groups.

 

Read Full Statement

 

Resources

Media

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service